Photo courtesy of Bangkok Post

Thailand's Department of Medical Services has announced that major hospitals including Rajavithi Hospital are ready to handle any cases of Nipah virus, even though no infections have been reported in the country so far. Dr. Nattapong Wongwiwat, the department's director-general, stated that hospitals such as Rajavithi, Nopparat Rajathanee, and Lerdsin have ramped up their preparedness. This includes ensuring the availability of medical resources, hospital beds, and setting up isolation facilities.

Rajavithi Hospital has implemented screening and emergency protocols, along with isolation areas for patients with moderate to severe symptoms. In response to public concerns in Pattaya, health teams have begun gathering samples from fruit bat colonies for testing. On Thursday, these samples were collected to be analyzed for any traces of Nipah virus, with results pending.

Bangkok Hospital Siriroj in Phuket has refuted social media rumors about seven infected Indian nationals, confirming no Nipah virus cases at their facility. The hospital continues to conduct rigorous screening and maintain alertness. Meanwhile, the Indian Embassy in Thailand has stated that since December 2025, only West Bengal has reported two confirmed Nipah cases, with subsequent testing of 196 contacts yielding negative results.

Increased vigilance is evident as Thailand's public health authorities have intensified monitoring efforts. Recently, 1,700 tourists were screened at various international airports without any infections detected. Authorities have enforced stricter measures for incoming travelers at Suvarnabhumi, Don Mueang, and Phuket airports to prevent any potential spread of the virus, reported Bangkok Post.

Key Takeaways

• Major hospitals in Thailand are prepared for potential Nipah virus cases.

• Screening and monitoring are intensified at airports and suspected bat colonies.

• No confirmed Nipah cases have been detected in Thailand so far.

Related Stories

Thailand Heightens Alert Over Nipah Virus After India Outbreak

Thailand Revives Covid-Style Controls Amid Nipah Virus Alert

  

Adapted by ASEAN Now from Bangkok Post 2026-01-29

 

 

It is surely needed, as there is an outbreak again in India of 2 cases in more than a billion people... I am more afraid of the UK Superflu, which will come with the British tourists, but that is no news....

This virus nests in Asia in countries like India, Thailand, Lagos etc... but there is no known treatment yet. The medication administered is mainly to apease the symptoms but if it's a bad case of the virus, it can create deeper complications or even be lethal depending.

There is no vaccine or cure for Nipha. Transmission vectors are direct contact with infected fruit bats, pigs, and humans.

Understanding Nipah Virus: Symptoms and Treatment

Nipah virus, a zoonotic pathogen from the Paramyxoviridae family, poses a significant public health threat, particularly in Asia where annual outbreaks occur in regions like Bangladesh and India. Transmitted primarily from fruit bats to humans or through intermediate hosts like pigs, the virus can also spread person-to-person via close contact with infected individuals or contaminated body fluids. High-risk groups include agricultural workers handling pigs, healthcare providers, and those consuming bat-contaminated food or beverages.

The incubation period for Nipah virus infection typically ranges from 4 to 14 days, though rare cases may manifest months or years later as latent infections. Initial symptoms often mimic common respiratory illnesses, including fever, headache, cough, sore throat, difficulty breathing, and vomiting. As the disease progresses, severe neurological complications such as encephalitis can develop, leading to disorientation, seizures, coma, and potentially death. Mortality rates are alarmingly high, ranging from 40% to 75%, underscoring the urgency of early intervention.

Diagnosis of Nipah virus is challenging due to nonspecific early signs but is crucial for outbreak control. Healthcare professionals should suspect Nipah in symptomatic patients from endemic areas. Testing involves real-time polymerase chain reaction (RT-PCR) from swabs, fluids, or blood during acute phases, transitioning to enzyme-linked immunosorbent assay (ELISA) for antibodies in later stages or recovery.

Currently, no licensed treatments exist for Nipah virus; management focuses on supportive care, including hydration, rest, and symptom relief. Promising developments include the monoclonal antibody m102.4, which has undergone phase 1 trials and been used compassionately, and remdesivir, shown effective in preventing infection in animal models. Ribavirin was trialed in past outbreaks, but its efficacy remains uncertain. Survivors may experience long-term effects like persistent convulsions or personality changes.

Prevention strategies emphasize personal protective equipment (PPE) for healthcare workers, such as gowns, gloves, eye protection, and N95 respirators. Public education on avoiding bat habitats and contaminated products is essential to mitigate risks.

(Word count: 298)

Key Takeaways

• High Mortality and Transmission Risks: Nipah virus causes severe encephalitis with a 40-75% fatality rate and spreads from bats to humans, often via pigs or person-to-person contact in endemic Asian regions.

• Symptom Progression and Diagnosis: Early signs include fever and respiratory issues, escalating to neurological complications; diagnosis relies on RT-PCR and ELISA tests for timely detection.

• Treatment and Prevention Focus: Supportive care is standard, with emerging therapies like m102.4 showing promise; PPE and public awareness are key to preventing outbreaks.

Original source: https://www.cdc.gov/nipah-virus/hcp/clinical-overview/index.html